Emergent Biosolutions (ER4) Q2 2026 Earnings Report

The call reflected a balance of strong near-term operational execution and financial results—Q2 revenue and adjusted EBITDA materially exceeded expectations, driven by accelerated MCM deliveries and improved margins—alongside significant commercial headwinds in the naloxone business that prompted a $191M noncash impairment and a downward revision to full-year revenue and profitability guidance. Management is taking proactive restructuring and capital allocation actions (debt refinancing, share repurchases, $40M annualized cost-savings plan) to preserve liquidity and position the company for 2027, but the naloxone competitive dynamics and guidance cuts temper the otherwise strong quarter.

Emergent revised full‑year 2026 guidance downward, lowering total revenue to $645–$675M (prior $720–$760M) and trimming adjusted EBITDA to $130–$150M (prior $155–$175M), while forecasting a GAAP net loss of $(245)–(225)M and adjusted net income of $10–$30M; adjusted gross margin is expected at 42%–44% and Q3 revenue is guided to $110–$130M. The update reflects increased competitive pressure in naloxone (NARCAN), a noncash NARCAN impairment of ~ $191M taken in Q2, and announced restructuring actions expected to yield ~ $40M of annualized savings (with ~ $11M of costs to achieve). For context, Q2 revenue was $234M and YTD revenue $390M, Q2 adjusted EBITDA was $97M (41% margin) and YTD adjusted EBITDA $132M (34% margin); Q2 adjusted gross margin was 58% (YTD 56%); quarter‑end cash was $140M with $190M total liquidity, gross debt $590M, net debt $450M (net leverage 1.9x), the company collected ~$145M of A/R in July, repurchased 1.1M shares for ~$9M in Q2 (YTD 1.9M for ~$18M, $37.5M remaining), and sold an underutilized building for roughly $6–6.4M.